Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Stock Information for Cannara Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cannara Biotech Inc.

Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
Cannara Announces Grant of Options and RSUs
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield
Cannara Biotech Enhances Financial Flexibility Through Strategic Asset Sale
Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.